Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 1, 2010, Pages 113-120

  Van Himbergen, Thomas M ^a   Otokozawa, Seiko ^a   Matthan, Nirupa R ^b   Schaefer, Ernst J ^a   Buchsbaum, Aaron ^a   Ai, Masumi ^a   Van Tits, Lambertus J H ^c   De Graaf, Jacqueline ^c   Stalenhoef, Anton F H ^c  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cholesterol; Familial combined hyperlipidemia; Lipids; Sterols

Indexed keywords

CAMPESTEROL; CHOLESTANOL; CHOLESTEROL; DESMOSTEROL; LATHOSTEROL; SITOSTEROL; SQUALENE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; GAS LIQUID CHROMATOGRAPHY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTANOL; CHOLESTEROL; DESMOSTEROL; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PHYTOSTEROLS; SEX CHARACTERISTICS; SITOSTEROLS; SQUALENE;

EID: 73849137508     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.196550     Document Type: Article

References (45)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
2. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:20252033.
3. Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, Hunt SC. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: A case-control comparison from the national heart, lung, and blood institute family heart study. Circulation. 2003;108:519-523.
4. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism. 1976;25:313-320.
5. Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L, Huber K, Widhalm K, Abdolvahab F, Sodeck G, Maurer G, Schillinger M. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (2009) 30, 1073-1079.
6. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest. 1980;10:17-22.
7. Kissebah AH, Alfarsi S, Evans DJ. Low density lipoprotein metabolism in familial combined hyperlipidemia. mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis. 1984;4:614-624.
8. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993;13: 1110-1118.
9. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apoli-poprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160-168.
10. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003;23: 1289-1294.
11. Bredie SJ, Kiemeney LA, de Haan AF, Demacker PN, Stalenhoef AF. Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet. 1996;58:812-822.
12. Hokanson JE, Krauss RM, Albers JJ, Austin MA, Brunzell JD. LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1995;15:452-459.
13. Vakkilainen J, Jauhiainen M, Ylitalo K, Nuotio IO, Viikari JS, Ehnholm C, Taskinen MR. LDL particle size in familial combined hyperlipidemia: Effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res. 2002;43:598-603.
14. de Graaf J, van der Vleuten GM, ter Avest E, Dallinga-Thie GM, Stalenhoef AF. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2007;92: 1269-1275.
15. Aouizerat BE, Allayee H, Cantor RM, Davis RC, Lanning CD, Wen PZ, Dallinga-Thie GM, de Bruin TW, Rotter JI, Lusis AJ. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet. 1999;65:397-412.
16. Pajukanta P, Terwilliger JD, Perola M, Hiekkalinna T, Nuotio I, Ellonen P, Parkkonen M, Hartiala J, Ylitalo K, Pihlajamaki J, Porkka K, Laakso M, Viikari J, Ehnholm C, Taskinen MR, Peltonen L. Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet. 1999;64:1453-1463.
17. Naukkarinen J, Ehnholm C, Peltonen L. Genetics of familial combined hyperlipidemia. Curr Opin Lipidol. 2006;17:285290.
18. Sniderman A, Williams K, Haffner S, Sattar N. Insights from apoB: From better diagnosis & therapy to the medusa hypothesis. Atheroscler Suppl. 2004;5:19-24.
19. Sniderman AD, Zhang XJ, Cianflone K. Governance of the concentration of plasma LDL: A reevaluation of the LDL receptor paradigm. Atherosclerosis. 2000;148:215229.
20. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37: 439-447.
21. Matthan NR, Lichtenstein AH. Approaches to measuring cholesterol absorption in humans. Atherosclerosis. 2004;174:197-205.
22. Matthan NR, Raeini-Sarjaz M, Lichtenstein AH, Ausman LM, Jones PJ. Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hyper-cholesterolemic women. Lipids. 2000;35:1037-1044.
23. Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990; 131:20-31.
24. van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50:730-739.
25. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Per-evozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943-1948.
26. Veerkamp MJ, de Graaf J, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: Results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;22:274-282.
27. Veerkamp MJ, de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation. 2004;109: 2980-2985.
28. van Himbergen TM, van Tits LJ, Ter Avest E, Roest M, Voorbij HA, de Graaf J, Stalenhoef AF. Paraoxonase (PON1) is associated with familial combined hyperlipidemia. Atherosclerosis. 2008;199:87-94.
29. Kimura H. Immunoassay with stable polystyrene latex particles. J Immunol Methods. 1980;38:353-360.
30. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008;101:315-318.
31. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007;53:2128-2135.
32. Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, Jones PH, Schaefer EJ. Effects of intensive atorvastatin and rosuv-astatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009;205:197-201.
33. Matthan NR, Giovanni A, Schaefer EJ, Brown BG, Lichtenstein AH. Impact of simvastatin, niacin, and/or antioxidants on cholesterol me-tabolism in CAD patients with low HDL. J Lipid Res. 2003;44: 800-806.
34. Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest. 2003;33:976-982.
35. Chan YM, Varady KA, Lin Y, Trautwein E, Mensink RP, Plat J, Jones PJ. Plasma concentrations of plant sterols: Physiology and relationship with coronary heart disease. Nutr Rev. 2006;64:385-402.
36. Cabezas MC, de Bruin TW, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hy-perlipidemia. Arterioscler Thromb. 1993;13:804-814.
37. de Graaf J, Veerkamp MJ, Stalenhoef AF. Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J R Soc Med. 2002;95 Suppl 42:46-53.
38. Asztalos BF, Swarbrick MM, Schaefer EJ, Dallal GE, Horvath KV, Ai M, Stanhope KL, Austrheim-Smith I, Wolfe BM, Ali M, Havel PJ. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. In press.
39. Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC, Hobbs HH. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006;281:27816-27826.
40. Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 2005;1:231-244.
41. Peri A, Serio M. Neuroprotective effects of the alzheimer's disease-related gene seladin-1. J Mol Endocrinol. 2008;41:251-261.
42. Garcia-Otin AL, Cofan M, Junyent M, Recalde D, Cenarro A, Pocovi M, Ros E, Civeira F. Increased intestinal cholesterol absorption in autosomal dominant hypercholesterolemia and no mutations in the low-density lipoprotein receptor or apolipoprotein B genes. J Clin Endocrinol Metab. 2007;92:3667-3673.
43. van der Vleuten GM, Isaacs A, Hijmans A, van Duijn CM, Stalenhoef AF, de Graaf J. The involvement of upstream stimulatory factor 1 in dutch patients with familial combined hyperlipidemia. J Lipid Res. 2007; 48:193-200.
44. Rada-Iglesias A, Ameur A, Kapranov P, Enroth S, Komorowski J, Gingeras TR, Wadelius C. Whole-genome maps of USF1 and USF2 binding and histone H3 acetylation reveal new aspects of promoter structure and candidate genes for common human disorders. Genome Res. 2008;18:380-392.
45. Allayee H, Krass KL, Pajukanta P, Cantor RM, van der Kallen CJ, Mar R, Rotter JI, de Bruin TW, Peltonen L, Lusis AJ. Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res. 2002;90:926-931.